Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

by · The Markets Daily

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research note released on Friday. The firm issued a hold rating on the medical research company’s stock.

Several other equities research analysts have also recently commented on the company. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th.

Get Our Latest Research Report on Cytosorbents

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.04 on Friday. The firm has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.00. The company has a market cap of $56.48 million, a price-to-earnings ratio of -1.76 and a beta of 0.51. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71.

Cytosorbents (NASDAQ:CTSO – Get Free Report) last released its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. During the same quarter in the prior year, the firm posted ($0.14) EPS. Research analysts predict that Cytosorbents will post -0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently modified their holdings of CTSO. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the 3rd quarter valued at $51,000. Sargent Investment Group LLC increased its position in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the last quarter. CM Management LLC grew its stake in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares during the period. Finally, Avenir Corp increased its stake in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after purchasing an additional 121,294 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

(Get Free Report)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Recommended Stories